Rare disease drugmaker · part of Sumitomo Pharma · based in Cary, United States · founded 2016 · enzyvant.com
Enzyvant Therapeutics works on Congenital Athymia, one of the rare diseases we track. It also has 1 FDA-approved rare disease drug.
Enzyvant, a subsidiary of Sumitomo Pharma, develops regenerative medicine therapies for rare pediatric immune system disorders. The company's FDA-approved RETHYMIC is a groundbreaking therapy that implants processed thymus tissue to rebuild immune function in children with congenital athymia.
Enzyvant Therapeutics pipeline
Each row lists the diseases Enzyvant Therapeutics is studying at that stage, from the ones closest to approval down to the earliest work.
We did not find active Enzyvant Therapeutics trials for the rare diseases we track on ClinicalTrials.gov right now.
Follow a condition Enzyvant Therapeutics is studying
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Enzyvant Therapeutics. Unsubscribe anytime.
You'll get, for Congenital Athymia:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
As a rare disease specialist, Enzyvant Therapeutics has active clinical trial programs and drug development efforts across 1 rare diseases, including Congenital Athymia. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Enzyvant Therapeutics, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Enzyvant Therapeutics is headquartered in Cary, United States, founded in 2016, a subsidiary of Sumitomo Pharma. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Rare diseases Enzyvant Therapeutics works on
Each disease page lists every open trial, not only Enzyvant Therapeutics's, plus approved treatments.
Congenital athymia is an ultra-rare condition in which a baby is born without a functioning thymus gland, the organ essential for developing T cells.
How common: Approximately 17 to 24 new cases per year in the U.S.; estimated fewer than 500 living patients
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Enzyvant Therapeutics's own site is enzyvant.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Enzyvant, a subsidiary of Sumitomo Pharma, develops regenerative medicine therapies for rare pediatric immune system disorders. The company's FDA-approved RETHYMIC is a groundbreaking therapy that implants processed thymus tissue to rebuild immune function in children with congenital athymia.
Enzyvant Therapeutics has active programs across 1 rare disease: Congenital Athymia. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
Yes. Enzyvant Therapeutics is a rare disease specialist headquartered in Cary, United States, founded in 2016. The company focuses primarily on developing treatments for rare and orphan diseases, with programs targeting Congenital Athymia. It operates as part of Sumitomo Pharma.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Enzyvant Therapeutics, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
Enzyvant Therapeutics has 1 FDA-approved drug with a rare disease use that we track, as of November 2026.
Source: the FDA's openFDA label database, matched to the rare diseases on Trial Friend; the list updates automatically and can include older products.
Yes, for 1 of its FDA-approved rare disease medicine that we track, each checked on Enzyvant Therapeutics' own website.
Rethymic: RETHYMIC Connect, 877-738-4962. Offers copay help with private insurance and insurance help. Checked November 2, 2026.
Medicare and Medicaid: drugmaker copay cards are limited to private insurance, so people with government coverage usually look to a free medicine program or a charity fund, both on the help paying page.
Eligibility is decided by each program, so call the number listed before a prescription is filled.
Enzyvant Therapeutics was founded in 2016 and is headquartered in Cary, United States. The company has been active for 10 years. It is a subsidiary of Sumitomo Pharma. As a rare disease specialist, the company dedicates its resources to developing therapies for patients with rare and orphan conditions.